Serum PAI-1 levels in type 2 diabetic patients on sitagliptin treatment
Not Applicable
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000004656
- Lead Sponsor
- Yokohama City University, Graduate School of Medicine
- Brief Summary
We investigated a possible association between serum plasminogen activator inhibitor-1 (PAI-1) levels and renal dysfunction in 124 type 2 diabetes patients. Multiple linear regression analyses indicated that the PAI-1 levels were significantly inversely correlated with estimated glomerular filtration rate (eGFR) independent of albuminuria, BMI, LDL-C, and triglyceride.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1> patient treated with insulin injection 2> patient treated with GLP-1 receptor agonists
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PAI-1
- Secondary Outcome Measures
Name Time Method